Zhen-Yu Zhou

Zhen-Yu Zhou


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2026 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
SWSu-Ping Wang
Su-Ping Wang
YYYuan Yuan
Yuan Yuan
PZPeng-Yu Zhong
Peng-Yu Zhong
ZZZhen-Yu Zhou
Zhen-Yu Zhou
Background: Managing ischemic cardiomyopathy-related ventricular tachycardia (VT) remains clinically challenging since no definitive consensus exists regarding the optimal therapeutic approach. Therefore, this study aimed to assess the safety and efficacy of catheter ablation for VT in patients with ischemic cardiomyopathy. Methods: We systematically searched the PubMed, EMBASE, and Cochrane Library databases to identify pertinent clinical trials. We selected the relative risk (RR) and mean difference (MD) as the effect measures, which were calculated using Review Manager software. Additionally, we used trial sequential analysis to assess each outcome. Results: Our study included six randomized controlled trials with 1064 patients. Catheter ablation was found to reduce the risk of the composite endpoint (RR 0.83, 95% confidence interval (CI) 0.74–0.94; p = 0.002), cardiac hospitalizations (RR 0.82, 95% CI 0.71–0.95; p = 0.007), and adverse events (RR 0.75, 95% CI 0.62–0.91; p = 0.003). Additionally, no significant differences were observed between the two groups regarding VT recurrence (RR 0.94, 95% CI 0.83–1.06; p = 0.33), appropriate implantable cardioverter-defibrillator (ICD) shocks (RR 0.85, 95% CI 0.72–1.01; p = 0.06), or all-cause mortality (RR 0.93, 95% CI 0.73–1.18; p = 0.53). Conclusions: Catheter ablation reduced the incidence of composite endpoints, cardiac hospitalizations, and adverse events related to VT in patients with ischemic cardiomyopathy. However, no statistically significant differences were found between the two groups for VT recurrence, appropriate ICD shocks, and all-cause mortality. The PROSPERO Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251011744.

18 September 2026 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
QYQingyi Yang
Qingyi Yang
YGYi Guan
Yi Guan
YZYanling Zhang
Yanling Zhang
ZZZhen-Yu Zhou
Zhen-Yu Zhou
Background: Contrast-induced nephropathy (CIN) is a common complication following coronary angiography (CA) or percutaneous coronary intervention (PCI) and is associated with prolonged hospitalization and adverse clinical outcomes. Remote ischemic preconditioning (RIPC), a noninvasive and nonpharmacological intervention, has been proposed as a potential strategy for preventing CIN. However, evidence from randomized controlled trials (RCTs) remains inconsistent. Methods: This meta-analysis of RCTs aimed to evaluate the efficacy of RIPC for preventing CIN in patients undergoing CA or PCI. The primary outcome was the incidence of CIN. For dichotomous outcomes, risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using the Mantel–Haenszel fixed-effect model. For continuous outcomes, standardized mean differences (SMDs) with 95% CIs were pooled using a fixed-effect model when heterogeneity was low and a random-effects model when substantial heterogeneity was present. Trial sequential analysis was performed for dichotomous outcomes to estimate the robustness of the cumulative evidence and the required information size. This study was prospectively registered with PROSPERO (CRD420251269657). Results: Twenty-six RCTs including 4,169 participants were included. Overall, RIPC significantly reduced the risk of CIN compared with the control treatment (RR 0.49, 95% CI 0.41–0.59, P < 0.00001; I 2 = 0%). Regarding renal function, RIPC significantly attenuated postprocedural increases in serum creatinine levels (SMD −1.00, 95% CI −1.60 to −0.39, P = 0.001) and was associated with lower postprocedural serum creatinine levels (SMD −0.23, 95% CI −0.39 to −0.08, P = 0.003). RIPC was also associated with a lower risk of major adverse events (MAEs) (RR 0.55, 95% CI 0.41–0.75, P = 0.0001). No significant differences were observed in postprocedural eGFR, neutrophil gelatinase-associated lipocalin (NGAL), cystatin C, all-cause mortality, dialysis requirement, or rehospitalization. Conclusion: In patients undergoing coronary angiography or percutaneous coronary intervention, RIPC was associated with reduced risks of CIN and MAEs, attenuated postprocedural increases in serum creatinine levels, and lower postprocedural serum creatinine levels, while evidence for postprocedural eGFR, NGAL, cystatin C, and clinical outcomes remains inconclusive. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251269657 , PROSPERO CRD420251269657.

22 October 2021 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
ZZZhen-Yu Zhou
Zhen-Yu Zhou
YCYu Chen
Yu Chen
DZDongying Zhang
Dongying Zhang
SWShiyong Wu
Shiyong Wu
TLTao Liu
Tao Liu
SQShu Qin
Shu Qin
[This corrects the article DOI: 10.1155/2019/1342190.].